Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | S100A4 | P26447 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28051431 | 0.98 | HCAR3 (0.57) | HCAR3HTTKDM4ECDC25BEGFR | |
| Phosphonic Acid SCHEMBL27298730 | 0.92 | HCAR3 (0.55) | HCAR3HTTKDM4ECDC25BEGFR | |
| SCHEMBL29888063 | 0.88 | HCAR3 (0.46) | HCAR3HTTKDM4ECDC25BEGFR | |
| SCHEMBL626410 | 0.85 | MAPT (0.54) | HCAR3HTTKDM4ECDC25BEGFR | |
| SCHEMBL29569609 | 0.85 | MAPT (0.54) | HCAR3HTTKDM4ECDC25BEGFR | |
| SCHEMBL16126356 | 0.81 | MAPK1 (0.48) | HCAR3HTTKDM4EABCB1ABCC1 | |
| SCHEMBL2616937 | 0.81 | MAPK1 (0.48) | HCAR3KDM4EABCB1ABCC1MAPK1 | |
| SCHEMBL3746067 | 0.81 | KDM4E (0.46) | HCAR3HTTKDM4EEGFRABCB1 | |
| SCHEMBL594213 | 0.81 | HCAR3 (0.61) | HCAR3HTTKDM4EMAPK1PKM | |
| SCHEMBL2707255 | 0.81 | HCAR3 (0.61) | HCAR3KDM4EABCB1ABCC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119684227-A | The method comprises the following steps of18Synthesis method of F-fluoromethol labeling precursor | 国电投核素同创(重庆)科技有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-108727276-A | Benzimidazole derivatives and their preparation | 江苏理工学院 | 2018-11-02 | — | — | CN | claimed |
| CN-108689945-A | Preparation method of benzimidazole derivative | 江苏理工学院 | 2018-10-23 | — | — | CN | claimed |
| CN-105399683-B | Benzimidazole derivatives and process for preparing the same | 江苏理工学院 | 2018-07-20 | — | — | CN | claimed |
| CN-105399683-A | Benzimidazole derivatives and process for preparing the same | UNIV JIANGSU TECHNOLOGY | 2016-03-16 | — | — | CN | claimed |
| EP-3976604-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2026-01-21 | — | — | EP | disclosed |
| US-12509455-B2 | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12492188-B2 | 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| EP-1602648-B2 | Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same | IDEMITSU KOSAN CO (JP) | 2025-03-26 | — | — | EP | disclosed |
| CN-119684227-A | The method comprises the following steps of18Synthesis method of F-fluoromethol labeling precursor | 国电投核素同创(重庆)科技有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119684227-A | The method comprises the following steps of18Synthesis method of F-fluoromethol labeling precursor | 国电投核素同创(重庆)科技有限公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-4200292-B1 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2024-11-13 | — | — | EP | disclosed |
| US-6908935-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040082625-A1 | Calcium receptor modulating agents | AMGEN INC. | 2004-04-29 | — | — | US | disclosed |
| US-6200976-B1 | FOR TREATING THROMBOSIS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-03-13 | — | — | US | disclosed |
| EP-1071669-A1 | BICYCLIC COMPOUNDS HAVING AN ANTI-THROMBITIC EFFECT | Boehringer Ingelheim Pharma KG (DE) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999054313-A1 | BICYCLIC COMPOUNDS HAVING AN ANTI-THROMBITIC EFFECT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-10-28 | — | — | WO | disclosed |
| US-4138572-A | Malonanilic derivatives | ROUSSEL UCLAF (FR) | 1979-02-06 | — | — | US | disclosed |
| US-4001408-A | SUBSTITUTED HETEROCYCLIC COMPOUNDS, PROCESSES AND COMPOSITION INCLUDING THOSE | ROUSSEL-UCLAF (FR) | 1977-01-04 | — | — | US | disclosed |
| US-3984398-A | 1,5-Benzodiazepine-2,4-diones | ROUSSEL-UCLAF (FR) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082625-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | HCAR3 52/4885HTT 2232/4885KDM4E 3394/4885 |
| US-12492188-B2 | 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis | TLR9, TLR1, TLR7 | HCAR3 2625/4885HTT 4807/4885KDM4E 781/4885 |
| US-12509455-B2 | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof | JAK1, JAK2, JAK3 | HCAR3 2533/4885HTT 1718/4885KDM4E 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.